Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2019-05-15 Earnings Release
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
Earnings Release 2019
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing financial results for the quarter ended March 31, 2019. The document itself does not contain the full financial statements or detailed financial analysis but rather references a press release as an exhibit. The length of the document is 4087 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, a document that announces or furnishes a press release about financial results without containing the full financial data should be classified as an Earnings Release (ER).
2019-05-15 English
Proxy Solicitation & Information Statement 2019
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as a 'Definitive Additional Materials' proxy statement for Ritter Pharmaceuticals, Inc. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The form DEFA14A corresponds to additional proxy solicitation materials. Given these characteristics, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is relatively short (2307 characters), consistent with proxy materials rather than a full annual report or other extensive filings.
2019-04-26 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2019-04-26 English
Annual Report 2018
Annual Report FY 2018
2019-04-01 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing the financial results for the year ending December 31, 2018, and that the press release is furnished as an exhibit. The document itself does not contain the full financial statements or detailed financial analysis but rather references the press release. The length of the document is 3857 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes a press release of financial results without containing the full report itself should be classified as a Regulatory Filing (RNS), as it does not contain the full Annual Report (10-K) or detailed financial data. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-03-29 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions "Item 8.01 Other Events" and describes the completion of enrollment in a Phase 3 clinical trial, along with a press release attached as an exhibit. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is not a certification or a proxy statement, nor does it relate to board changes, dividends, or mergers. Given the nature of the Form 8-K and the content, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-03-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.